

1/10




Fig. 1




Fig. 2




Fig. 3

3/10




Fig. 4




Fig. 5




Fig. 6




Fig. 7

5/10




Fig. 8




Fig. 9







Fig. 11




N=3 experiments
**P < 0.01 vs. T1D serum; *p < 0.05 vs T1D serum

Fig. 12



N=3 experiments
**P < 0.001 vs. T1D serum


Fig. 13



** p<0.01 IGFBP3 vs untreated

Experiments performed in triplicates in Beta-lox5 cultured for 72 h

Fig. 14



**** p<0.0001 IGFBP3 vs untreated, TM1, TC01;

**p<0.01 IGFBP3 vs. antiTMEM219 commercial

Experiments performed in triplicates in Beta-lox5 cultured for 72 h

Fig. 15

9/10




Fig. 16




Fig. 17

10/10




Fig. 18




Fig. 19